KCT0006897招募中未知
A randomized, open-label, single dose, crossover clinical study to investigate the effect of food on the pharmacokinetics of EL-1804 in healthy adult subjects
Elyson Pharmaceutical0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 55(Year)（—）
- 性别
- All
入选标准
- •1) Healthy adult subject`s age 19~55 years at screening
- •2) BMI 18.0~29.0kg/m2 and weight more than 50kg
- •3) Subject who don`t have congenital or chronic disease and have no abnormal medical examination results
- •4) Suitable subject who is determined by ECG and laboratory test
- •5) Subject who fully understand the clinical trials after in-depth explanation given prior to the clinical study, decided to join the clinical trials by their will and signed consent form which approved by IRB
排除标准
- •1) Subjects who have clinically significant or a history of cardiovascular, respiratory, hepatic, kidneys, neurological, endocrine, blood, psychiatric or urinary disease
- •2) Subjects who have a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption
- •3) Subjects with hereditary diseases of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •4) Subjects with a history of hypersensitivity or clinically significant hypersensitivity to drugs containing the active ingredients or components of the IP or other drugs such as aspirin, antibiotics, etc.
- •5) Subjects who show hypotension(SBP<90mmHg) or hypertension(SBP>150mmHg or DBP>95mmHg) at the screening
- •6) Subjects with following results;
- •- AST or ALT > 2 times upper limit of normal range
- •- Total bilirubin > 2.0mg/dL
- •- eGFR < 60mL/min<1.73m2
- •7) Subjects who drink continually (more than 21units/wee, 1unit=10g=12.5mL of per alcohol) or who can`t drink during the clinical trial period
- •8) Subjects who continue to smoke (more than 10 cigaratte/day) or who can`t smoke during the hospitalization for the clinical trial period
- •9) Subjects who take the medication involved in other clinical trials or bio-equivalence study within 6 months before the first administration day
- •10) subjects who have donated whole blood within 60 days, or a component blood donation within 30 days or received blood transfusion within 30 days before the first administration day
- •11) Subjects who have taken any prescription or herbal medicine within 14 days or any OTC within 7 days before the first administration day
- •12) Subjects who have taken drug metabolizing enzyme-inducing and suppressing drugs such as barbital drugs within 1 month before first administration day
- •13) Subjects who have a diet (particularly grapefruit juice or its products) within 7 days prior to the first administration day that may affect the absorption, distribution, metabolism and excretion of the drug
- •14) Subjects who don`t agree to exclude the possibility of pregnancy using a medically recognized contraceptive method from the first administration day to 7 days after the last administration of the IP
- •15) A metal patient, and a drug addict
- •16) Subjects who are unwilling or unable to comply to diet and lifestyle required in the clinical trail
- •17) Subjects who have clinically significant abnormalities as a result of other clinical laboratory tests or who edged the person in charge of clinical trail to be ineligible for participation in the clinical trail due to other reason such as non-compliance of instruction, uncooperative attitude, and others
- •18) Positive finding in pregnant or serum/urine hCG test, or lactating women
研究者
相似试验
已完成
不适用
clinical study to compare the pharmacokinetic characteristics and the safety between oral administration of formulation of bepotastine in healthy adult male subjectsDiseases of the skin and subcutaneous tissueKCT0003652Inha University Hospital30
已完成
不适用
Clinical study to compare the pharmacokinetic characteristics and the safety between Tenelitin tablet 20 mg and Tenelia tablet 20 mg in healthy adult subjectsKCT0003832Kyung Dong Pharmaceutical36
已完成
不适用
Clinical study to compare the effect of food on the pharmacokinetic characteristics and the safety after oral administration of SR formulation of bepotastine in healthy adult subjectsDiseases of the skin and subcutaneous tissueKCT0004393Chungbuk National University Hospital30
已完成
不适用
A clinical trial to investigate safety/tolerability and pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 tablets) compared to co-administration of Evogliptin 5 mg and Metformin XR 1000 mg after single oral administration in healthy male volunteersEndocrine, nutritional and metabolic diseaseKCT0001692Dong-A ST36
已完成
不适用
The aim of this study is to compare and evaluate the pharmacokinetic properties and safety of oral administration of KD4002Endocrine, nutritional and metabolic diseasesKCT0007759Kyung Dong Pharmaceutical32